John Bridgeman
Chief Scientific Officer Immunokey
Dr. John Bridgeman is an immunotherapy expert with over 20 years of experience translating scientific concepts into clinical therapies. He holds a PhD from the University of Manchester with advanced training at Cardiff University and brings deep expertise in CAR biology and gene engineering. John has established and led R&D teams, driven projects from concept to Phase 1 trials, and managed robust IP portfolios. With a strong record in patent generation, funding, and collaboration, he is dedicated to advancing T-cell therapies in immuno-oncology.
Seminars
Wednesday 2nd December 2026
Evidence – Using Translational Models to Overcome Tumour Antigen Heterogeneity & Improve CAR-T Responses in Solid Tumours
8:30 am
- Understanding how tumour antigen heterogeneity contributes to resistance and variable patient responses in CAR-T therapy
- Leveraging translational model systems to evaluate strategies that overcome antigen escape and improve therapeutic durability
- Applying insights from the CARKey platform to develop more consistent and clinically meaningful responses across diverse patient populations
Wednesday 2nd December 2026
Insights Exchange – What Drives Confidence in Translational Decision Making?
8:50 am
- Which datasets provide the greatest confidence when progressing a candidate?
- How can teams determine whether a preclinical signal is meaningful enough to justify investment?
- What are the biggest barriers to translating promising biology into clinical success?
- Audience Q&A
